4.7 Article

Bacteraemic pneumococcal pneumonia and SARS-CoV-2 pneumonia: differences and similarities

期刊

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2021.11.023

关键词

Community-acquired pneumonia; Bacteraemic pneumococcal pneumonia; SARS-CoV-2; Process of care; Mortality; Survival

向作者/读者索取更多资源

This study compared the clinical presentation and outcomes between bacteraemic pneumococcal community-acquired pneumonia (B-PCAP) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. The results showed that B-PCAP patients had more severe disease, while the mortality rate was higher for SARS-CoV-2 pneumonia. More effective treatments are needed for patients with SARS-CoV-2 pneumonia.
Objective: To analyse differences in clinical presentation and outcome between bacteraemic pneumococcal community-acquired pneumonia (B-PCAP) and sSvere Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pneumonia. Methods: This observational multi-centre study was conducted on patients hospitalized with B-PCAP between 20 00 and 2020 and SARS-CoV-2 pneumonia in 2020. Thirty-day survival, predictors of mortality, and intensive care unit (ICU) admission were compared. Results: In total, 663 patients with B-PCAP and 1561 patients with SARS-CoV-2 pneumonia were included in this study. Patients with B-PCAP had more severe disease, a higher ICU admission rate and more complications. Patients with SARS-CoV-2 pneumonia had higher in-hospital mortality (10.8% vs 6.8%; P=0.004). Among patients admitted to the ICU, the need for invasive mechanical ventilation (69.7% vs 36.2%; P<0.001) and mortality were higher in patients with SARS-CoV-2 pneumonia. In patients with B-PCAP, the predictive model found associations between mortality and systemic complications (hyponatraemia, septic shock and neurological complications), lower respiratory reserve and tachypnoea; chest pain and purulent sputum were protective factors in these patients. In patients with SARS-CoV-2 pneumonia, mortality was associated with previous liver and cardiac disease, advanced age, altered mental status, tachypnoea, hypoxaemia, bilateral involvement, pleural effusion, septic shock, neutrophilia and high blood urea nitrogen; in contrast, >= 7 days of symptoms was a protective factor in these patients. In-hospital mortality occurred earlier in patients with B-PCAP. Conclusions: Although B-PCAP was associated with more severe disease and a higher ICU admission rate, the mortality rate was higher for SARS-CoV-2 pneumonia and deaths occurred later. New prognostic scales and more effective treatments are needed for patients with SARS-CoV-2 pneumonia. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据